The US Food and Drug Administration (FDA) has released the results from its 2022–2024 sampling and analysis program, which confirms the integrity of Ecuadorian shrimp exports. The program, which focused on economically motivated adulteration, specifically short-weighting, in imported frozen seafood, found that no Ecuadorian shrimp samples exhibited violations. Using the AOAC Method 963.18, the agency assessed compliance with net weight declarations. The results showed that all of the shrimp products samples, those originating from Ecuador had no short‑weighting violations – meaning the actual net weight matched the declared net weight on the label. The positive findings affirm the rigorous standards upheld in Ecuadorian shrimp exports and highlight the importance of compliance with international requirements.